174 related articles for article (PubMed ID: 37164128)
1. Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer.
Sutera PA; Shetty AC; Hakansson A; Van der Eecken K; Song Y; Liu Y; Chang J; Fonteyne V; Mendes AA; Lumen N; Delrue L; Verbeke S; De Man K; Rana Z; Hodges T; Hamid A; Roberts N; Song DY; Pienta K; Ross AE; Feng F; Joniau S; Spratt D; Gillessen S; Attard G; James ND; Lotan T; Davicioni E; Sweeney C; Tran PT; Deek MP; Ost P
Ann Oncol; 2023 Jul; 34(7):605-614. PubMed ID: 37164128
[TBL] [Abstract][Full Text] [Related]
2. Identification of a Predictive Genomic Biomarker for Prostate-directed Therapy in Synchronous Low-volume Metastatic Castration-sensitive Prostate Cancer.
Sutera P; Shetty AC; Song Y; Hodges T; Hoang T; Rana Z; Pienta K; Feng F; Song DY; DeWeese T; Gillessen S; Sweeney C; James N; Attard G; Deek M; Tran PT
Eur Urol Oncol; 2024 Apr; 7(2):241-247. PubMed ID: 37558543
[TBL] [Abstract][Full Text] [Related]
3. Survival of Patients with Metastatic Prostate Cancer After Disease Progression on an Androgen Receptor Axis-Targeted Therapy Given in the Metastatic Castration-Sensitive Versus Metastatic Castration-Resistant Prostate Cancer Setting.
Sayegh N; Tripathi N; Nussenzveig RH; Thomas VM; Tandar C; Goel D; Nordblad B; Sahu KK; Li H; L Maughan B; Agarwal N; Swami U
Eur Urol Focus; 2023 Jan; 9(1):106-109. PubMed ID: 35835693
[TBL] [Abstract][Full Text] [Related]
4. Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: A subgroup analysis of the randomised clinical TITAN study.
Merseburger AS; Agarwal N; Bhaumik A; Lefresne F; Karsh LI; Pereira de Santana Gomes AJ; Soto ÁJ; Given RW; Brookman-May SD; Mundle SD; McCarthy SA; Uemura H; Chowdhury S; Chi KN; Bjartell A
Eur J Cancer; 2023 Nov; 193():113290. PubMed ID: 37708629
[TBL] [Abstract][Full Text] [Related]
5. TP53 structure-function relationships in metastatic castrate-sensitive prostate cancer and the impact of APR-246 treatment.
Hoang T; Sutera P; Nguyen T; Chang J; Jagtap S; Song Y; Shetty AC; Chowdhury DD; Chan A; Carrieri FA; Hathout L; Ennis R; Jabbour SK; Parikh R; Molitoris J; Song DY; DeWeese T; Marchionni L; Ren L; Sawant A; Simone N; Lafargue A; Van Der Eecken K; Bunz F; Ost P; Tran PT; Deek MP
Prostate; 2024 Jan; 84(1):87-99. PubMed ID: 37812042
[TBL] [Abstract][Full Text] [Related]
6. Real-world survival outcomes of adding docetaxel or abiraterone in patients with high-volume metastatic castration-sensitive prostate cancer: historically controlled, propensity score matched comparison with androgen deprivation therapy.
Narita S; Kimura T; Hatakeyama S; Hata K; Yanagisawa T; Maita S; Chiba S; Sato H; Kashima S; Koizumi A; Yamamoto R; Takayama K; Okane K; Ishida T; Horikawa Y; Kumazawa T; Shimoda J; Suzuki T; Ohyama C; Egawa S; Nomura K; Habuchi T
World J Urol; 2022 May; 40(5):1135-1141. PubMed ID: 35218371
[TBL] [Abstract][Full Text] [Related]
7. Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics.
Sutera P; Van Der Eecken K; Kishan AU; Hamid A; Grist E; Attard G; Lotan T; Mendes AA; Paller CJ; Carducci MA; Ross A; Wang H; Pienta K; Feng FY; Antonarakis ES; Ost P; Song DY; Greco S; Deville C; DeWeese T; Tran PT; Deek MP
Prostate Cancer Prostatic Dis; 2022 Apr; 25(4):713-719. PubMed ID: 35013522
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Value of Germline DNA Repair Gene Mutations in De Novo Metastatic and Castration-Sensitive Prostate Cancer.
Wei Y; Wu J; Gu W; Wang J; Lin G; Qin X; Dai B; Gan H; Ye D; Zhu Y
Oncologist; 2020 Jul; 25(7):e1042-e1050. PubMed ID: 32190957
[TBL] [Abstract][Full Text] [Related]
9. Apalutamide for metastatic castration-sensitive prostate cancer: final analysis of the Asian subpopulation in the TITAN trial.
Chung BH; Huang J; Uemura H; Choi YD; Ye ZQ; Suzuki H; Kang TW; He DL; Joung JY; Brookman-May SD; McCarthy S; Bhaumik A; Singh A; Mundle S; Chowdhury S; Agarwal N; Ye DW; Chi KN; Uemura H
Asian J Androl; 2023 Nov; 25(6):653-661. PubMed ID: 37322621
[TBL] [Abstract][Full Text] [Related]
10. Triplet therapy with androgen deprivation, docetaxel, and androgen receptor signalling inhibitors in metastatic castration-sensitive prostate cancer: A meta-analysis.
Ciccarese C; Iacovelli R; Sternberg CN; Gillessen S; Tortora G; Fizazi K
Eur J Cancer; 2022 Sep; 173():276-284. PubMed ID: 35964470
[TBL] [Abstract][Full Text] [Related]
11. Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy.
Sweeney CJ; Martin AJ; Stockler MR; Begbie S; Chi KN; Chowdhury S; Coskinas X; Frydenberg M; Hague WE; Horvath LG; Joshua AM; Lawrence NJ; Marx GM; McCaffrey J; McDermott R; McJannett M; North SA; Parnis F; Parulekar W; Pook DW; Reaume MN; Sandhu SK; Tan A; Tan TH; Thomson A; Tu E; Vera-Badillo F; Williams SG; Yip S; Zhang AY; Zielinski RR; Davis ID;
Eur Urol; 2021 Sep; 80(3):275-279. PubMed ID: 34030924
[TBL] [Abstract][Full Text] [Related]
12. Impact of Initial Timing of Metastatic Disease on Survival in Patients With Newly Diagnosed Metastatic Castration-Resistant Prostate Cancer Treated With Androgen Receptor Pathway Inhibitors.
Gebrael G; Sayegh N; Tripathi N; Goel D; McFarland T; Ebrahimi H; Nordblad B; Chigarira B; Mathew Thomas V; Sahu KK; Li H; Chehrazi-Raffle A; Kohli M; Agarwal N; Swami U; Maughan BL
Urol Pract; 2024 Jan; 11(1):32-35. PubMed ID: 37903742
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Systemic Treatment in Prostate Cancer Patients With Visceral Metastasis: A Systematic Review, Meta-analysis, and Network Meta-analysis.
Yanagisawa T; Rajwa P; Kawada T; Mori K; Fukuokaya W; Petrov P; Quhal F; Laukhtina E; von Deimling M; Bianchi A; Majdoub M; Pradere B; Kramer G; Kimura T; Shariat SF
J Urol; 2023 Sep; 210(3):416-429. PubMed ID: 37339479
[TBL] [Abstract][Full Text] [Related]
14. Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis.
Buonerba C; Ferro M; Dolce P; Crocetto F; Verde A; Lucarelli G; Scafuri L; Facchini S; Vaia A; Marinelli A; Terracciano D; Montella L; Longo N; Imbimbo C; Mirone V; Di Lorenzo G; De Placido S; Sonpavde G
Crit Rev Oncol Hematol; 2020 Jul; 151():102992. PubMed ID: 32474391
[TBL] [Abstract][Full Text] [Related]
15. External Validation of Association of Baseline Circulating Tumor Cell Counts with Survival Outcomes in Men with Metastatic Castration-Sensitive Prostate Cancer.
Swami U; Sayegh N; Jo Y; Haaland B; McFarland TR; Nussenzveig RH; Goel D; Sirohi D; Hahn AW; Maughan BL; Goldkorn A; Agarwal N
Mol Cancer Ther; 2022 Dec; 21(12):1857-1861. PubMed ID: 36198026
[TBL] [Abstract][Full Text] [Related]
16. SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis-Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer.
Swami U; Graf RP; Nussenzveig RH; Fisher V; Tukachinsky H; Schrock AB; Li G; Ross JS; Sayegh N; Tripathi N; Mathew Thomas V; Oxnard GR; Antonarakis ES; Agarwal N
Clin Cancer Res; 2022 Nov; 28(22):4917-4925. PubMed ID: 36088616
[TBL] [Abstract][Full Text] [Related]
17. Lower pretreatment serum testosterone level predicts poor prognosis in the patients with metastatic hormone-sensitive prostate cancer undergoing androgen deprivation therapy.
Yoshida T; Kawai T; Hagiwara K; Yanagida K; Noda M; Tokura Y; Yoshimura I; Kaneko T; Nakagawa T
Jpn J Clin Oncol; 2024 Apr; 54(4):498-503. PubMed ID: 38251778
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Upfront Docetaxel With Androgen Deprivation Therapy for Castration-Sensitive Metastatic Prostate Cancer Among Minority Patients.
Pathak S; Thekkekara R; Yadav U; Ahmed AT; Yim B; Lad TE; Mullane M; Batra KK; Aronow WS; Psutka SP
Am J Ther; 2020 May; 28(4):e380-e387. PubMed ID: 32384317
[TBL] [Abstract][Full Text] [Related]
19. Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial.
Hamid AA; Huang HC; Wang V; Chen YH; Feng F; Den R; Attard G; Van Allen EM; Tran PT; Spratt DE; Dittamore R; Davicioni E; Liu G; DiPaola R; Carducci MA; Sweeney CJ
Ann Oncol; 2021 Sep; 32(9):1157-1166. PubMed ID: 34129855
[TBL] [Abstract][Full Text] [Related]
20. Population-Based Study of Docetaxel or Abiraterone Effectiveness and Predictive Markers of Progression Free Survival in Metastatic Castration-Sensitive Prostate Cancer.
Briones J; Khan M; Sidhu AK; Zhang L; Smoragiewicz M; Emmenegger U
Front Oncol; 2021; 11():658331. PubMed ID: 34026638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
